- Stocks
- Pharma & Healthcare
- Fermenta Biotech
Fermenta Biotech share price
NSE: FERMENTAPharma & Healthcare
Fermenta Biotech at a glance
Fermenta Biotech (NSE: FERMENTA) closed at ₹456.75 on 19 Oct 2026, down 6.31% on the day. With a market capitalisation of ₹1,344 Cr, it ranks 1329th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector.
Its return on equity was 21.2% in FY25. Its 52-week range is ₹248.85 (4 May 2026) to ₹582.65 (6 Oct 2026); the last close is 21.6% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹122 Cr (−13.1% year on year) and net profit ₹19 Cr (−44.2%), on a consolidated basis. Promoters held 64.09% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹1,344 CrRank 1329 on NSE
- Price to book
- 2.2×FY25
- EPS (TTM)
- ₹24.99to Q4 FY26
- ROE
- 21.2%FY25
- ROCE
- 24.2%FY25
- Debt to equity
- 0.3FY25
- Net profit margin
- 16.3%FY25
- Book value / share
- ₹124.33FY25
- Dividend payout
- 4.7%FY25
- 52-week high
- ₹582.656 Oct 2026
- 52-week low
- ₹248.854 May 2026
- RSI (14-day)
- 34.9
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −6.31% | −12.4% | −1.7% | +3.1% | — |
Fermenta Biotech quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹78 Cr | ₹95 Cr | ₹156 Cr | ₹140 Cr | ₹136 Cr | ₹130 Cr | ₹137 Cr | ₹122 Cr |
| Revenue YoY | −5.2% | +67.0% | +58.1% | +43.7% | +74.4% | +37.0% | −12.2% | −13.1% |
| Net profit | −₹6 Cr | ₹11 Cr | ₹38 Cr | ₹33 Cr | ₹22 Cr | ₹18 Cr | ₹12 Cr | ₹19 Cr |
| Net profit YoY | −368.3% | — | +279.3% | — | — | +62.1% | −68.3% | −44.2% |
| Net margin | −7.6% | 11.7% | 24.2% | 23.8% | 15.9% | 13.8% | 8.8% | 15.3% |
| EPS | −₹2.01 | ₹3.94 | ₹12.71 | ₹11.79 | ₹7.49 | ₹6.48 | ₹4.36 | ₹6.66 |
Fermenta Biotech financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹293 Cr | ₹377 Cr | ₹399 Cr | ₹350 Cr | ₹336 Cr | ₹469 Cr |
| Operating profit | ₹43 Cr | ₹52 Cr | ₹27 Cr | −₹23 Cr | −₹2 Cr | ₹83 Cr |
| Net profit | ₹60 Cr | ₹43 Cr | ₹15 Cr | −₹54 Cr | −₹24 Cr | ₹76 Cr |
| EPS (₹) | ₹21.00 | ₹16.00 | ₹5.00 | −₹18.00 | −₹8.00 | ₹26.00 |
| Cash from operations | ₹34 Cr | ₹63 Cr | ₹43 Cr | ₹117 Cr | ₹105 Cr | ₹41 Cr |
| Total debt | ₹102 Cr | ₹110 Cr | ₹115 Cr | ₹84 Cr | ₹43 Cr | ₹15 Cr |
| Shareholders' equity | ₹309 Cr | ₹361 Cr | ₹372 Cr | ₹315 Cr | ₹289 Cr | ₹363 Cr |
Fermenta Biotech shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 64.09% | 64.09% | 64.09% | 64.09% | 64.09% | 64.09% |
| Foreign institutions | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.13% |
| Domestic institutions | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.04% |
| Non-institutions | 35.00% | 35.00% | 34.75% | 33.99% | 33.30% | 33.20% |
Fermenta Biotech vs peers
The listed Pharma & Healthcare companies nearest to Fermenta Biotech by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| AMRUTANJANAmrutanjan Health Care | ₹501.00 | −3.09% | −28.8% | ₹1,448 Cr | 25 | — |
| JAGSNPHARMJagsonpal Ser | ₹217.95 | −0.07% | −1.3% | ₹1,435 Cr | 34.5 | — |
| AHCLAnlon Healthcare | ₹26.92 | −0.22% | +108.5% | ₹1,431 Cr | 44.1 | — |
| TTKHLTCARETTK Healthcare | ₹1,007.60 | −2.93% | −12.2% | ₹1,424 Cr | 21.7 | — |
| SHALBYShalby | ₹126.00 | −2.33% | −49.9% | ₹1,361 Cr | 38.9 | — |
| KOPRANKopran | ₹279.00 | +2.01% | +61.2% | ₹1,347 Cr | 52.3 | — |
| FERMENTAFermenta Biotech | ₹456.75 | −6.31% | — | ₹1,344 Cr | — | — |
Ask anything about Fermenta Biotech
Pivot answers on the live chart with evidence you can check, and tests strategies against FERMENTA's own history. Try: “Why has FERMENTA moved over the last three months?” · “Backtest a 50-day moving-average crossover on FERMENTA over five years” · “Compare FERMENTA with AMRUTANJAN on margins and valuation”
Frequently asked questions about Fermenta Biotech
What is the share price of Fermenta Biotech today?
Fermenta Biotech (NSE: FERMENTA) last closed at ₹456.75 on 19 Oct 2026. Its 52-week high is ₹582.65 and its 52-week low is ₹248.85.
What is the market cap of Fermenta Biotech?
Fermenta Biotech's market capitalisation is ₹1,344 Cr (₹1,344 Cr) at the 19 Oct 2026 close, ranking 1329th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Fermenta Biotech?
Return on equity was 21.2% in FY25 and return on capital employed was 24.2% in FY25 (consolidated figures).
Is Fermenta Biotech a debt-free company?
No. Fermenta Biotech's debt-to-equity ratio was 0.3 in FY25, with total debt of ₹15 Cr.
What were Fermenta Biotech's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Fermenta Biotech reported revenue of ₹122 Cr, −13.1% year on year, and net profit of ₹19 Cr, −44.2% year on year.
What is the shareholding pattern of Fermenta Biotech?
As of 30 Jun 2026: promoters 64.09%, foreign institutions 0.13%, domestic institutions 0.04%, non-institutions 33.20%.
Who are Fermenta Biotech's competitors?
The listed Pharma & Healthcare companies closest to Fermenta Biotech by market cap are Amrutanjan Health Care, Jagsonpal Ser, Anlon Healthcare, TTK Healthcare, Shalby and Kopran.
Is Fermenta Biotech a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Fermenta Biotech's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on FERMENTA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with F · all NSE stocks · this page as text